论文部分内容阅读
早在20世纪初人们就开始将放射性粒子用于胰腺癌治疗,但由于使用的放射性粒子如226Ra针、198Au、192Ir和222Rn等放射生物学或放射物理学方面的局限性,植入技术和植入计划系统的不健全,使得粒子植入治疗胰腺癌发展缓慢。20世纪60年代末期随着125I粒子临床应用,放射性核素放射生物学及放射物理学特性的深入研究,三维治疗计划系统的飞速发展,术中超声技术的使用,使得粒子植入治疗胰腺癌再度回归。
As early as the early 20th century, people started to use radioactive particles for the treatment of pancreatic cancer, but due to the radiological or radiophysical limitations such as the use of radioactive particles such as 226Ra, 198Au, 192Ir and 222Rn, implantation and implantation Into the planning system is not perfect, making the particle implantation for the treatment of pancreatic cancer is developing slowly. With the clinical application of 125I particles, the radiobiological and radiophysiological characteristics of radionuclides in the late 1960s, the rapid development of three-dimensional treatment planning system and the use of intraoperative ultrasound technology have made the treatment of pancreatic cancer again with particle implantation return.